Annelise Wilhite, MD, explains what current treatment options look like for patients with vulvar/vaginal melanoma.
Annelise Wilhite, MD, gynecologic oncology fellow at the University of South Alabama Health explains what current treatment options look like for patients with vulvar/vaginal melanoma.
Treatment options mimic those of cutaneous melanoma due to the rarity of the disease and the lack of specific therapy guidelines for vulvar/vaginal melanoma. Since few patients develop this disease, Wilhite explains that it is difficult to have new clinical trials as the same individuals are always involved.
Finding treatments that work is the main obstacle in this patient population, and further understanding the differences between those 2 diseases is crucial for future developments.
In addition to treatments similar to that of cutaneous melanoma, hematologists who specialize in melanoma are contacted to provide their feedback on a patient’s individual case, and tumors are sent out for molecular profiling.
Transcription:
0:08 | The treatment involves surgical resection, and then for metastatic or unresectable disease or locally advanced disease. Typically, chemotherapy or immuno oncology therapy is recommended. As of now, the frontline agents for cutaneous melanoma are PD-1 inhibitors CTLA-4 inhibitors and a combination of BRAF and MEK inhibitors. Full of rational melanoma, the treatment typically involves a multidisciplinary approach. We will often follow the cutaneous melanoma guidelines.
Managing Expectations of Treatment for Infiltrative Basal Cell Carcinoma
November 10th 2023In an event comoderated by Michael K. Wong, MD, PhD, FRCPC, and Anokhi Jambusaria, MD, MSCE, the 2 key opinions leaders discussed the hypothetical patient case of an 88-year-old man with a nonhealing ulcer on the lateral aspect of his nose who received a diagnosis of infiltrative basal cell carcinoma.
Read More
Adjuvant Cemiplimab Shows Survival Benefit For Responders in CSCC
October 21st 2023One-year follow-up of the phase 2 study assessing the use of neoadjuvant and adjuvant cemiplimab in patients with cutaneous squamous cell carcinoma shows a promising survival benefit that has led to a wider phase 3 study.
Read More
Addressing Skin Cancer: From Screening to Treatment
May 20th 2023In an interview with Targeted Oncology, Meredith McKean, MD, MPH of Sarah Cannon Research Institute reviewed the recent changes to the U.S. Preventive Services Task Force skin cancer screening guidelines, and discussed advances in the skin cancer treatment paradigm for those who could not prevent the disease.
Read More